Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Histologically proven hepatocellular carcinoma.~2. HCC underwent curative resection within 6 weeks before registration.~3. Grossly, the resection margin should be \> 1 cm.~4. Tumors, either single, \< 5 cm in size or no more than 3 for size \< 3 cm.~5. Patients must have a performance status of ECOG score \< 2.~6. Patients must have adequate liver reservation and adequate hemogram.~   * Pugh-Child's Score \< 7.~  * The serum total bilirubin level are \< 2 mg/dl.~  * The prothrombin times are \< 3 sec above normal control.~  * The platelet are \> 7.5 x 104 / mm3.~  * The WBC are \> 3,000 / mm3.~7. Patient must have serum creatinine \< 1.5 mg/dl~8. Cardiac function with NYHA classification \< Grade II~9. HBsAg (+) .~10. Signed informed consent.~Exclusion Criteria:~1. Patients who have non-curative resection are not eligible.~2. Resected HCCs with histologically positive margins are not eligible.~3. HCCs with radiological evidence of portal vein thrombus are not eligible.~4. Patients with other systemic diseases which required concurrent usage of glucoticosteroid or immunosuppressant agent(s) are not eligible.~5. Patients with advanced second primary malignancy are not eligible.~6. Patients with pregnancy or breast-feeding are not eligible.~7. Patients with severe cardiopulmonary diseases are not eligible.~8. Patients with clinically significant psychiatric disorder are not eligible.~9. Patients who had antineoplastic chemotherapeutic or immuno-therapeutic drugs or corticosteroids within 6 weeks of commencing the protocol are not eligible.~10. Patients who had prior lamividine and/or adefovir dipivoxil therapy are not eligible.~11. Anti-HCV positive patients are not eligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).